Abstract

Objective

To assess time-trends and outcomes of hallucinogen use disorder hospitalizations.

Methods

The U.S. National Inpatient Sample (NIS) data from 1998 to 2014 were used. People hospitalized with hallucinogen use disorder as primary or secondary diagnosis were assessed. Rates were calculated per 100,000 NIS claims. Multivariable-adjusted logistic regression analyses assessed the association of patient and hospital characteristics with outcomes.

Results

The national U.S. rates per 100,000 total NIS claims for hallucinogen use disorder hospitalizations increased from 1998–2000 to 2013–2014 and outcomes worsened over time:^{1 Addy PH, D’Souza DC. Chapter 54: hallucinogen use disorders. In: Ebert MH, Leckman JF, Petrakis IL, editors. Current diagnosis and treatment: psychiatry (pp. 735–743). 3rd ed. New York (NY): McGraw-Hill Education; 2019. [Google Scholar]} hospitalizations, from 22.8 to 40.4 (1.8-fold);^{2 Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016;73(1):39–47. doi:https://doi.org/10.1001/jamapsychiatry.2015.2132.[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]} in-hospital mortality rate, from 0.3 to 0.6 (2.3-fold); and^{3 Heslin KC, Elixhauser A, Steiner CA. Hospitalizations involving mental and substance use disorders among adults, 2012. Rockville (MD): Agency for Healthcare Research and Quality; 2015. Statistical Brief #191. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. [Google Scholar]} non-home discharge, from 4.2 to 6.3 (1.5-fold), respectively. Various patient and hospital characteristics were associated with worse healthcare utilization outcomes and in-hospital mortality.

Conclusions

Hallucinogen use disorder hospitalizations were common and increased from 1998 to 2014 in the U.S. interventions targeting modifiable patient and hospital factors can potentially reduce this burden.

中文翻译：

---

致幻剂使用障碍住院的流行病学：一项为期 17 年的美国国家研究

摘要

客观的

评估致幻剂使用障碍住院的时间趋势和结果。

方法

使用了 1998 年至 2014 年的美国国家住院样本 (NIS) 数据。对以致幻剂使用障碍为主要或次要诊断住院的人进行了评估。费率按每 100,000 份 NIS 索赔计算。多变量调整逻辑回归分析评估了患者和医院特征与结果的关联。

结果

从 1998-2000 年到 2013-2014 年，美国每 100,000 例 NIS 致幻剂使用障碍住院索赔的比率有所增加，结果随着时间的推移而恶化：^{1 Addy PH，D'Souza DC。 第54章：致幻剂使用障碍。在：Ebert MH，Leckman JF，Petrakis IL，编辑。当前的诊断和治疗：精神病学（第 735-743 页）。第 3 版。纽约（NY）：麦格劳-希尔教育；2019 年。 [Google Scholar]}住院率，从 22.8 到 40.4（1.8 倍）；^{2 Grant BF、Saha TD、Ruan WJ、Goldstein RB、Chou SP、Jung J、Zhang H、Smith SM、Pickering RP、Huang B等。DSM-5 药物使用障碍的流行病学：来自全国酒精和相关疾病流行病学调查的结果-III。JAMA 精神病学。2016 年；73(1)：39 – 47。doi：https://doi.org/10.1001/jamapsychiatry.2015.2132。[Crossref]、[PubMed]、[Web of Science®]、[  Google Scholar]}院内死亡率，从 0.3 到 0.6（2.3 倍）；和^{3 Heslin KC，Elixhauser一个，施泰纳CA. 涉及成人精神和物质使用障碍的住院情况，2012 年。Rockville (MD)：医疗保健研究和质量机构；2015 年。统计简报#191。医疗保健成本和利用项目 (HCUP) 统计简报。 【Google Scholar】}非居家放电，分别从4.2到6.3（1.5倍）。各种患者和医院特征与较差的医疗保健利用结果和住院死亡率相关。

结论

致幻剂使用障碍住院治疗很常见，并且从 1998 年到 2014 年在美国针对可改变患者和医院因素的干预措施中有所增加，可以潜在地减轻这种负担。